[11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trialXilin Wu, Morris J. Brown, Daniel M. Berney et al.|Nature Medicine|2023Cited by 137
A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[<sup>18</sup>F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary AldosteronismDaniel Gillett, Mark Gurnell, Russell Senanayake et al.|Journal of Nuclear Medicine|2025Cited by 11
Novel radiolabeled ligand, Para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate (CETO) compared to [<sup>11</sup>C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)Emily Goodchild, Morris J. Brown, Russell Senanayake et al.|Endocrine Abstracts|2022Cited by 1
Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two yearsEmily Goodchild, Morris J. Brown, Xi‐Lin Wu et al.|Endocrine Abstracts|2022Cited by 0
11C-metomidate PET CT versus Adrenal Vein Sampling for diagnosing surgically curable primary aldosteronism: prospective test validation, and impact of somatic genotype and ethnicity on outcomesXilin Wu, Morris J. Brown, Russell Senanayake et al.|Research Square|2021Cited by 0